ReviewCold Spring Harbor perspectives in medicine2015
Prevention of hepatitis B.
Review in Cold Spring Harbor perspectives in medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 73 citations in OpenAlex.
- Coverage and determinants of hepatitis B virus vaccine uptake among children aged 12-36 months in Ethiopia: an analysis of the 2016 Ethiopian Demographic and Health Survey.International health · 2026Article
- Global immunisation planning and economic development potential: a panel data analysis for the macroeconomic impact of hepatitis B vaccination from 2000 to 2018.BMC medicine · 2026Article
- Primary Liver Cancer Trends Worldwide and in China: Analysis of GLOBOCAN 2022 Data and Disease Management Implications.Portal hypertension & cirrhosis · 2026Review
- Healthcare Workers' Experiences With Hepatitis B Virus Post-Exposure Prophylaxis Management at a Military Hospital in Ghana: A Qualitative Study.Health science reports · 2026Article
- Review
- Article
- Article
- The descriptive epidemiology and projection of liver cancer in adolescents and young adults: findings from the global burden of disease study 2021.Frontiers in medicine · 2025Article
- Hepatitis B prevalence and risk factors among adults living with HIV in South Africa: a clinic-based cohort study.BMC infectious diseases · 2024Article
- Antiviral Therapy of Chronic Hepatitis B Virus between Present and Future.Journal of clinical medicine · 2024Review
- Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030.Vaccines · 2024Review
- HBV Vaccines: Advances and Development.Vaccines · 2023Review
- Seroconversion of hepatitis B vaccine among patients from outpatient clinic in Georgia.Vaccine: X · 2023Article
- Knowledge, Attitude and Practice Among Palestinian Healthcare Workers in the Gaza Strip Towards Hepatitis B: Cross-sectional survey.Sultan Qaboos University medical journal · 2023Article
- "Titer of anti-HBs in health professions trainees: prevalence of antibody coverage in a University of Central Italy".Human vaccines & immunotherapeutics · 2022Observational
- Assessment of Hepatitis B Vaccination Status and Associated Factors among Healthcare Workers in Bosaso, Puntland, Somalia 2020.BioMed research international · 2022Article
- Detection and Prevention of Virus Infection.Advances in experimental medicine and biology · 2022Article
- Biosensing based on field-effect transistors (FET): Recent progress and challenges.Trends in analytical chemistry : TRAC · 2020Review
- Knowledge, awareness, attitude, and practice of health-care professionals toward hepatitis B disease and vaccination in Saudi Arabia.Human vaccines & immunotherapeutics · 2019Article
- Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) causes life-threatening liver disease. It is transmitted through a horizontal route or a mother-to-infant route, and the latter is the major route in endemic areas. Prevention of HBV infection by immunization is the best way to eliminate HBV-related diseases. The HBV vaccine is the first human vaccine using a viral antigen from infected persons, which is safe and effective. Either passive immunization by hepatitis B immunoglobulin (HBIG) or active immunization by HBV vaccine is effective, and a combination of both yields the best efficacy in preventing HBV infection. The impact of universal HBV immunization is huge, with 90%-95% effectiveness in preventing chronic HBV infection. It is the first cancer preventive vaccine with a protective efficacy against hepatocellular carcinoma (HCC) of ∼ 70%. Nevertheless, further effort is still needed to avoid vaccine failure and to increase the global coverage rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.